Trial record 37 of 126 for: "Acute Leukemia" | "Antimetabolites, Antineoplastic"
Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02269579|
Recruitment Status : Withdrawn
First Posted : October 21, 2014
Last Update Posted : March 14, 2018
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
|Recruitment Status :||Withdrawn|
|Estimated Primary Completion Date :||June 2017|
|Estimated Study Completion Date :||June 2017|